Malady Kyle

EVP Malady Kyle (VZ Business CEO) sold 20,000 shares at $40.49 on 2025-01-28; stock now $39.47.

Malady Kyle, EVP and Group CEO-VZ Business, sold 20,000 shares on 2025-01-28 at $40.49, reducing his holdings by 43.8% to 25.7K shares. The sale occurred when VZ was trading near its 52-week range ($37.81–$45.21), and the stock has since declined 1.3% over 30 days. His same-ticker history at VZ shows mixed timing: prior sells on 2024-02-22 and 2024-02-15 produced 90-day returns of -2.5% and +0.4% respectively, with 1 of 2 prior sales well-timed at the 90-day horizon. His cross-ticker track record reflects a 50.00% well-timed rate across 3 prior sales. The timing context is modest—near but not at a 52-week peak—and prior outcomes at this ticker provide limited predictive clarity on insider intent or market direction.

VZ EVP Kyle Malady sold 20,000 shares at $40.54 on 2025-01-27, reducing holdings to 45.7K shares (-30.5%)

Kyle Malady, EVP and Group CEO-VZ Business, executed a discretionary open-market sale of 20,000 shares for $810.8K on 2025-01-27, reducing his position from 65.7K to 45.7K shares—a -30.5% reduction in holdings. The sale occurred at $40.54, while the stock currently trades at $40.28, indicating no material price movement since the transaction. Across Malady's prior three same-ticker sales at VZ, only 1 of 2 measurable outcomes showed negative 90-day returns (well-timed by the standard that stock declines after executive sales). His cross-ticker track record across all tickers shows a 50.00% well-timed rate for sells with an average 90-day return of -1.0%, neither pattern strong enough to signal acute market timing acumen. The company's annual revenue is declining (-2.1% year-over-year) and the stock is trading at 10.9% below its 52-week high, providing some context for a substantial reduction in insider equity exposure.